Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Vanda Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: Vanda issued a press release disclosing that "[o]n September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Vanda's New Drug Application (NDA) of tradipitant for the treatment of symptoms in gastroparesis, providing Vanda with a Complete Response Letter (CRL)." Following this news, Vanda's stock price fell sharply during intraday trading on September 19, 2024.
In order to be eligible to join the VNDA class action lawsuit, you must have incurred a loss on shares of Vanda Pharmaceuticals Inc. purchased during the class period listed above.
TOP
